Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

REC-2282 · AR-42

Small molecule · Inhibitor of histone deacetylase · developed by Recursion Pharmaceuticals

Phase 2/3 Most advanced trial (none active)
RXRX Developer
1 Registered trials

What is REC-2282?

REC-2282 is an orally available phenylbutyrate-derived small molecule that inhibits histone deacetylase (HDAC) catalytic activity. This leads to chromatin histone hyperacetylation, altered gene expression and induction of tumor cell apoptosis. It is being studied in neurofibromatosis type 2.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AR-42, OSU-HDAC42, NSC-D736012
Drug type
Small molecule
Targets
histone deacetylase
Mechanism
Inhibitor of histone deacetylase
Pathways
chromatin remodeling, tumor suppressor gene transcription, apoptosis
Therapy area
Oncology
Developer
Recursion Pharmaceuticals Inc. (RXRX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
E0GG29V0AQ

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05130866 Phase 2/3 Neurofibromatosis Type 2 Terminated RXRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Neurofibromatosis Type 2

More from Recursion Pharmaceuticals

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the RXRX page.

Follow RXRX, the company behind REC-2282

See RXRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RXRX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.